Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Clinical trial NCT01218126 · COMPLETED
Trial details
- NCT number
- NCT01218126
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-11-04
- Primary completion
- 2011-12-21
- Enrollment
- 604
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.